Reduced-intensity-conditioning (RIC) regimens have allowed older patients to have allogeneic hemopoietic progenitor cell transplantation (HCT). This retrospective study was done to assess the impact of the HCTcomorbidity index (HCT-CI) in addition to other pretransplant factors on the outcome of RIC transplants. In all 121 such patients were transplanted between 2002 and 2008 at two centers using fludarabine, melphalan and alumtuzumab conditioning. The OS and non-relapse mortality (NRM) were 56% and 30% at 2 years, respectively. The NRM of patients with HCT-CI X3 was not significantly different from the NRM of those with HCT-CI 0-2 (P value 0.24). Age and disease status at transplantation were significant factors affecting OS (P value 0.07 and 0.008, respectively), with no impact on NRM (P value 0.14 and 0.24, respectively). Although HCT-CI on its own did not independently predict NRM or survival, taken together with age and disease status at transplantation, it can be utilized to further delineate RIC allograft recipients into groups with different outcomes. Patients with none or one of these three adverse factors (ageX60 years, leukemia in second CR or PR/high-risk myelodysplasia (MDS) and HCT-CIX3) had a 2-year NRM and survival of 18% and 80%, respectively, which was significantly better than those of patients with two or more of these adverse factors with 2-year NRM and survival of 46% (P value 0.03) and 40% (P value 0.02), respectively. None of the patients with all three adverse factors (ageX60 years, leukemia in second CR or PR/ high-risk MDS and HCT-CIX3) had survived for 2 years (median survival 12 months). This information can be used to guide patient selection for RIC transplants and to appropriately counsel patients of the risks and benefits of this treatment.
Introduction
Leukemia affecting older individuals causes considerable treatment dilemmas. It is well known now that many older patients developing acute leukemia or myelodysplasia (MDS) possess poor risk features, such as high-risk cytogenetic and molecular abnormalities. 1 Hence, treatment outcomes for this group of patients with conventional chemotherapy, despite achieving good remission rates, remain poor for both newly diagnosed and relapsed disease. [2] [3] [4] [5] Allo-SCT is considered to be the favored treatment for such high-risk leukemia and MDS, but its utility is limited to younger fitter patients. 6, 7 A high risk of non-relapse mortality (NRM) is an important limiting factor in myeloablative transplants, especially in recipients 450 years of age. 8 Non-myeloablative or reduced-intensity-conditioning (RIC) regimens are associated with a lower toxicity and have allowed older patients, often with other comorbidities, to undergo SCT. 6, [9] [10] [11] This allows the possibility of long-term disease-free survival (DFS) and possible cure in diseases where the outcome of conventional treatments is poor. 6, 12 The selection of conditioning regimen (myeloablative, reduced intensity or nonmyeloablative) on the basis of age cutoffs alone is, however, not thought to be optimal when predicting NRM and survival. 13, 14 Other factors, such as disease status and co-morbidities, may also affect NRM and survival and hence may need to be taken into account. 13 A number of risk-assessment scores have been utilized to predict NRM and outcomes of HCT. [15] [16] [17] [18] These comorbidity scores, such as haemopoietic progenitor cell transplantation (HCT)-comorbidity index (CI), have been validated in some studies to be useful in predicting NRM in transplant candidates in the setting of myeloablative compared with non-myeloablative transplants, albeit in a heterogenous group of patients receiving myeloablative and non-myeloablative TBI-based conditioning regimens. 15, 18, 19 In others, it was not found to be predictive of mortality on its own in HCT. 20, 21 Patients having RIC allografts are, however, very heterogeneous as far as degree of comorbidity is concerned, and it is unclear whether these comorbidity scores can further delineate groups of RIC allograft recipients who will have significantly different NRM and survival.
This retrospective study was done to assess the outcomes of Alemtuzumab and non-TBI-based RIC transplantation in patients with MDS and leukemia based on their comorbidity scores. The collected data were also analyzed to assess for other factors that may independently affect NRM and OS post-RIC allograft.
Subjects and methods

Selection criteria
The study included 121 patients with MDS, AML, ALL and CML undergoing RIC allograft. Patients included were those who had RIC transplants with fludarabine, melphalan and campath conditioning, with PBSC as stem cell source, in adults over 18 years of age. These were consecutive patients transplanted between December 2002-December 2008 in Nottingham University Hospital and between February 2006-December 2008 in University Hospital Birmingham. Exceptions/exclusions were those who received any different RIC conditioning (n ¼ 7), BM or cord blood as stem cell source (n ¼ 22) and those with insufficient data, for instance, required for HCT-CI score (n ¼ 5). Minimal follow-up data required were age, sex, variables included in HCT-CI, stem cell source, donor type, degree of HLA match, donor and recipient CMV serostatus, date of transplant, disease status at transplant, disease type, whether alive or dead at date of analysis, date and cause of death.
Patient characteristics
The characteristics of the 121 patients are shown in Table 1 . The median age at transplantation was 58 years (20-69.3 years), with a median follow-up of 15 months (1-76). Most of the patients were transplanted for acute leukemia (83). In all, 65% were in first CR (CR1), 25% in second CR (CR2) and 10% in PR at the time of transplantation. There were 22 MDS patients and 16 CML patients who underwent RIC allogeneic transplants. The majority of the CML patients undergoing allogeneic transplants were atypical CML patients (Ph chromosome negative). This is because of a sharp drop in typical Ph chromosome-positive patients having allogeneic transplants especially with RIC since the introduction of tyrosine kinase inhibitors. In all 77 out of the 121 patients were CMV-positive transplants. Only recipients receiving PBSCs were included. Also, 64 patients received stem cells from unrelated matched donors.
Degree of HLA matching
Volunteer unrelated donors were HLA matched by using high-resolution tissue typing. Out of the 64 unrelated transplants, 47 were fully matched (10/10) transplants. Also, 15 were single-allele-mismatched (9/10) transplants and 2 were two-allele-mismatched (8/10) transplants.
All related transplants were fully HLA matched by lowresolution tissue typing.
CMV serostatus CMV-negative transplants were the ones in which both donor and recipients were seronegative for CMV IgG. CMV-positive transplants were those in which either donor or recipient or both were CMV IgG seropositive.
Disease status at transplantation Disease status at transplantation for the purpose of this study was defined as follows:
High risk: PR/CR2 or more for AML, high-risk MDS (RAEB I/II), second chronic phase or advanced-stage CML.
Low risk: CR1, low-risk MDS (RA, RCMD).
Conditioning regimens
Fludarabine, melphalan and campath conditioning regimen (fludarabine 30 mg/m 2 on days À9 to À5, campath 1H 10 mg i.v. on days À5 to À1 and melphalan 140 mg/m 2 on day À2) was used in all patients. Hence, our findings may only be translatable to patients undergoing RIC transplants with campath T-cell depletion and may not be applicable to other T-cell-depleting strategies where GVHD is more frequent. 
HCT-CI comorbidity scores
The different parameters constituting HCT-CI are shown in Table 2 . A review of case notes and computer records was done to obtain the data required to record the HCT-CI for each patient. The number of patients with scores of 0, 1, 2, 3 and X4 was 18, 20, 13, 28 and 42, respectively (Table 3) . Hence, the total number of patients with HCT-CI scores of 0-2 and X3 was 51 and 70, respectively. The total number of deaths in patients with HCT-CI score 0-2 was 16, out of which 5 died of disease relapse and the rest (11) had NRM. The total number of deaths in patients with HCT-CI score X3 was 33, out of which 11 had relapse deaths and the rest (21) had NRM (see Table 3 ). The most common comorbidity was pulmonary function impairment (33%), followed by impaired cardiac function (12%).
Statistical analysis NRM and OS curves were obtained separately for each group of patients with comorbidity scores of 0, 1, 2, 3 and X4 using GraphPad Prism version 5 (GraphPad, San Diego, CA, USA). Based on these NRM and OS curves for each group obtained, a comparison of NRM and OS was done between patients with scores of 0-2 vs scores X3 as NRM curves were different for patients with comorbidity scores of 0, 1 and 2 and patients with scores of 3 and X4 ( Figure 1 ). NRM was defined as any death other than due to relapsed disease, whereas OS analysis was based on all causes of mortality. Univariate analysis was done on SPSS 16.0 (SPSS, Chicago, IL, USA) to obtain P values with Pearson's correlation and Graph pad Prism to obtain hazard ratios and 95% confidence intervals. Multivariate analysis was done on SPSS to obtain P values using linear regression. Factors analyzed in addition to HCT-CI included age oor X60 years (based on median age), disease status at transplant (CR1 or CR2/PR for acute leukemia and chronic phase 1 or chronic phase 2/advanced phase for CML), CMV status and donor type (related/unrelated).
Patients were divided into three risk groups (good, intermediate and poor risk), based on presence of none/ one, two or all three of the significant adverse factors found on multivariate analysis, as follows:
Group 1 (good risk): Age o60 years, low-risk disease status, HCT-CI scores of p2; age o60 years, low-risk disease status, HCT-CI scores of X3.
Group 2 (intermediate risk): Age o60 years, high-risk disease status, HCT-CI scores of X3; age X60 years, highrisk disease status, HCT-CI scores of p2; age X60 years, low-risk disease status, HCT-CI scores of X3.
Group 3 (poor risk): Age X60 years, high-risk disease status, HCT-CI scores X3.
A comparison of NRM and OS between these three risk groups was performed with Graph pad Prism and survival curves were obtained.
Results
OS and DFS
Out of 121 patients, 49 had died by the time of analysis. The OS of the whole cohort was 56% at 2 years and DFS was 79% at 2 years. The OS of patients reduces as the comorbidity score increases (Figures 1a and b) and Abbreviation: NRM ¼ non-relapse mortality.
Role of HCT-comorbidity index, age and disease status SW Bokhari et al a comparison of survival curves of patients with scores 0-2 and X3 is shown (Figures 1c and d) .
Results of univariate and multivariate analyses of different factors affecting OS and DFS are shown in Table 4 . The 2-year OS and DFS of patients with score 0-2 were similar to those of patients with score X3 (that is, 68% vs 40%, and 82% vs 72%, respectively) and did not show any significant difference on univariate as well as multivariate analysis (P value 0.24 and 0.40, respectively). The comparison of OS curves is shown in Figures 1c and d . Patients with age X60 years had a lower OS of 43% vs 64% at 2 years for those o60 years, which showed a trend toward statistically significant difference on multivariate analysis (P value 0.07). Difference in DFS at 2 years was 68% vs 80%, which was statistically not significant (P value 0.77).
Disease status (CR1 vs CR2/PR, high-risk MDS and chronic phase 2 or more/advanced-stage CML) at transplantation proved to be a significant factor affecting OS (P value 0.008) and DFS (P value 0.05).
CMV-positive serostatus had a significantly better OS (P value 0.05), but with no impact on DFS.
Donor type (sibling or unrelated) had similar OS and DFS.
Mortality due to disease relapse
In all, 16 out of 49 deaths (33%) were due to relapsed disease. Of these, 5 had HCT-CI scores of 0-2 and 11 had HCT-CI scores of X3. There were 6 relapse deaths in patients with low-risk disease status at transplantation as compared with 10 in those with high-risk disease status.
Non-relapse mortality
The NRM of the entire cohort was 30% at 2 years. Results of univariate and multivariate analyses of factors affecting NRM are shown in Table 4 . The 2-year NRM percentage of patients with HCT-CI score 0-2 was lesser as compared with patients with score X3, that is, 28% vs 38% at 2 years. The difference, however, was not statistically significant on univariate as well as multivariate analysis (P value 0.24). The effect of age o60 years vs X60 years on NRM was also not statistically significant (P value 0.14). Similarly, disease status (CR1 vs CR2/PR and high-risk MDS) at transplantation was not a significant factor for NRM (P value 0.24). CMV status also did not prove to be a significant factor affecting NRM, with a 2-year NRM of CMVÀ vs þ transplants being 43% vs 25%, respectively (P value 0.25).
Multivariate analysis and results of risk-group stratification
In the multivariate analysis, HCT-CI comorbidity scores, although showing a trend, were not proven to be an independently significant factor affecting NRM. Age X60 years, high-risk disease status at transplantation and CMVpositive serostatus were found to be significant factors affecting OS (Table 4) .
Although HCT-CI score was not shown to be an independent predictive factor for NRM or survival, utilization of three patient-specific factors (age, disease status and HCT-CI) in combination can delineate patients into groups with distinct outcomes. We divided patients into three risk groups (good, intermediate and poor risk) based on presence of none/one, two or all three of these adverse factors, as described previously in the statistical analysis section. Patients with none or one of the above three adverse factors (group 1; n ¼ 41) had a 2-year NRM and survival of 18% and 80%, respectively, which was significantly better than those of patients with two of the above adverse factors (group 2; n ¼ 58), with a 2-year NRM and survival of 46% (P value 0.03) and 40% (P value 0.02), respectively. None of the patients with all three adverse factors (group 3; n ¼ 10) had survived for 2 years (median survival 12 months).
The NRM and survival curves of these three risk groups (good, intermediate and poor) are shown in Figures 2a and b .
Discussion
This study showed that the OS of the whole cohort of patients receiving a RIC allograft for leukemias and MDS with fludarabine, melphalan and campath conditioning was 56% at 2 years. This compares favorably with conventional treatment if given to this group of patients where OS rates of 10-15% are reported. 6 Similarly, the NRM of the whole cohort was 30% at 2 years, which compares favorably with myeloablative transplants. Older patients (450 years) with leukemia and MDS have been reported to have lower NRM with RIC allogeneic transplantation. 22, 23 Hence, RIC allograft is the preferred modality of treatment for MDS and leukemia in transplant-eligible patients as compared with myeloablative allogeneic transplantation in older (450 years) patients.
This study shows that patients requiring RIC transplants are actually quite heterogeneous as far as their co-morbidities are concerned, with quite a proportionate spread of comorbidity scores if HCT-CI is used. However, we failed to show any statistically significant impact of HCT-CI comorbidity scores on NRM or OS. Patients who underwent RIC allografts with comorbidity scores of X3 experienced a 2-year NRM of 38% compared with 28% in those with comorbidity scores of 0-2 (P value 0.24). In contrast, older age (X60 years) did have a trend towards a statistically significant effect on OS (P value 0.07) but not on NRM. This adverse effect of age on survival shown in our study conflicts with data from the Center for International Blood and Marrow Transplantation Research. 24 The disease status at transplantation also had an impact on OS, with patients with advanced diseases (CR2 or PR) having a significantly lower OS (P value 0.008) but with no significant effect on NRM.
These three patient-specific adverse factors (age 460 years, disease status at transplantation of CR2/PR/highrisk MDS and HCT-CI comorbidity scores X3) become even more significant in predicting both NRM and survival when taken together. Our study suggests that presence of two or more of these adverse factors predicts poor outcome. HCT-CI comorbidity scores of X3 do not seem to affect the outcomes unless there is another adverse factor present, such as older age or high-risk disease status. This is depicted by the survival curves of patients o60 years, low-risk disease status and HCT-CI o3 being no different from patients with HCT-CI X3. Rather than providing a general mortality figure of 15-20% for RIC transplants for MDS and leukemia, it would be more useful to predict a more precise mortality and survival rate for a given patient based on age, disease status and HCT-CI comorbidity score taken together. NRM and OS figures of patients divided into three distinct risk groups based on the presence of no or one (HCT-CI score 3 or more) adverse factor (good risk), two adverse factors (intermediate risk) or all three adverse factors (poor risk) can be used to counsel patients and making decisions regarding transplantation.
As mentioned previously, there have been a number of publications based largely on single-center retrospective studies, with conflicting results regarding the significance of HCT-CI comorbidity scores. Hence, it would be useful to further assess the usefulness of HCT-CI prospectively in a larger number of transplant recipients with a longer follow-up. Although older patients with leukemia and MDS have better outcomes with RIC transplantation as compared with conventional chemotherapy, those with a combination of two or more factors, that is, high HCT-CI comorbidity scores, age 460 years and high-risk disease status at transplantation, have high NRM and poor outcome even with RIC. In these groups different conditioning regimens or management strategies should be explored.
